Drug intelligence / Profile preview

autologous CD34+ cells

Development stage: Phase 3
Lead developer: Lisata Therapeutics
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intramyocardial

Overview

Autologous CD34+ cell therapy is a regenerative medicine approach involving the intramyocardial injection of a patient's own mobilized peripheral blood CD34+ hematopoietic stem cells. Developed significantly by Dr. Douglas Losordo at Northwestern University and later Caladrius Biosciences, the therapy aims to treat chronic myocardial ischemia and congestive heart failure. The mechanism of action is therapeutic angiogenesis, where the CD34+ cells promote the formation of new microvasculature (neovascularization) through direct incorporation into blood vessels and the paracrine release of angiogenic growth factors. This process improves myocardial perfusion and function in patients with refractory angina or ischemic heart failure.

Brand names: OLOGO
Other names: autologous CD34+ stem cellsbone marrow-derived CD34+ cellsCLBS14-CMDCLBS-14-CMDCLBS 14-CMD

Beyond the preview

Go deeper on autologous CD34+ cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous CD34+ cells.

Explore the full profile